NCT05255965View on ClinicalTrials.gov

IL-8+ naïve T Cells as a Biomarker for Thymoma Identification

CompletedOBSERVATIONAL

Enrollment

310

Participants

Timeline

Start Date

May 2, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions

Thymoma

Interventions

DIAGNOSTIC_TEST

level of IL-8+ initial T cells

5ml peripheral venous blood was taken before surgery or biopsy, and the levels of initial T cell with IL-8+, PLXND1+, PTK7+ or CR2+ were detected and recorded within 6 hours, respectively.

Trial Locations (1)

200032

180 Fenglin Road, Shanghai

All Listed Sponsors

lead

Shanghai Zhongshan Hospital

OTHER

NCT05255965 - IL-8+ naïve T Cells as a Biomarker for Thymoma Identification | Biotech Hunter | Biotech Hunter